HS-10296 hydrochloride |
Catalog No.GC33053 |
Le chlorhydrate d'almonertinib (HS-10296) est un inhibiteur de la tyrosine kinase EGFR de troisième génération, irréversible et disponible par voie orale, avec une sélectivité élevée pour les mutations de sensibilisation À l'EGFR et de résistance T790M. Le chlorhydrate de HS-10296 présente une grande activité inhibitrice contre T790M, T790M/L858R et T790M/Del19 (IC50 : 0,37, 0,29 et 0,21 nM, respectivement), et est moins efficace contre le type sauvage (3,39 nM). Le chlorhydrate de HS-10296 est utilisé pour la recherche sur le cancer du poumon non À petites cellules.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2134096-03-8
Sample solution is provided at 25 µL, 10mM.
HS-10296 hydrochloride is an orally available and third-Generation inhibitor of epidermal growth factor receptor (EGFR)-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
HS-10296 hydrochloride is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which canbe used to treat NSCLC[1]. Additionaly, HS-10296 could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q[2].
[1]. Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. [2]. Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38.
Average Rating: 5
(Based on Reviews and 5 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *